CY1122602T1 - Αντιμετωπιση των nafld και nash - Google Patents
Αντιμετωπιση των nafld και nashInfo
- Publication number
- CY1122602T1 CY1122602T1 CY20191101347T CY191101347T CY1122602T1 CY 1122602 T1 CY1122602 T1 CY 1122602T1 CY 20191101347 T CY20191101347 T CY 20191101347T CY 191101347 T CY191101347 T CY 191101347T CY 1122602 T1 CY1122602 T1 CY 1122602T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- nafld
- nash
- mbx
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978335P | 2014-04-11 | 2014-04-11 | |
| PCT/US2015/025416 WO2015157697A1 (en) | 2014-04-11 | 2015-04-10 | Treatment of nafld and nash |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122602T1 true CY1122602T1 (el) | 2021-03-12 |
Family
ID=53373532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101347T CY1122602T1 (el) | 2014-04-11 | 2019-12-20 | Αντιμετωπιση των nafld και nash |
Country Status (27)
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009288066B2 (en) | 2008-09-02 | 2015-12-24 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| ES2712052T3 (es) * | 2008-10-17 | 2019-05-09 | Cymabay Therapeutics Inc | Métodos para reducir partículas de LDL pequeñas y densas |
| DK3278665T3 (da) | 2009-04-29 | 2020-11-30 | Amarin Pharmaceuticals Ie Ltd | Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf |
| NZ807894A (en) | 2009-04-29 | 2025-08-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CA3129996C (en) | 2009-06-15 | 2025-09-02 | Amarin Pharmaceuticals Ireland Limited | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISED LDL-C LEVELS IN A SUBJECT UNDERGOING CONCOMITANT STATIN THERAPY |
| SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
| JP2015522029A (ja) | 2012-06-29 | 2015-08-03 | アマリン ファーマシューティカルス アイルランド リミテッド | スタチン療法中の患者における心血管系イベントの危険性を減少させる方法 |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) * | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| CN106102734B (zh) | 2014-03-20 | 2019-05-14 | 西玛贝医药公司 | 肝内胆汁淤积性疾病的治疗 |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| PL3129018T3 (pl) | 2014-04-11 | 2020-05-18 | Cymabay Therapeutics, Inc. | Leczenie NAFLD i NASH |
| CN106661548B (zh) | 2014-05-28 | 2020-12-11 | 儿童医院医疗中心 | 用于经由定向分化将前体细胞转化为胃组织的方法和系统 |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| WO2016061464A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intetine using pluripotent stem cells and methods of making and using same |
| HK1248537A1 (zh) * | 2015-03-26 | 2018-10-19 | T3D治疗有限责任公司 | 使用茚满乙酸衍生物治疗肝病的方法 |
| CN107530306A (zh) | 2015-04-28 | 2018-01-02 | 普罗诺瓦生物医药挪威公司 | 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途 |
| US10940125B2 (en) | 2015-09-18 | 2021-03-09 | Duke University | Methods and compositions for the treatment of steatosis-associated disorders |
| WO2017139708A1 (en) | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat nonalcoholic steatohepatitis (nash) |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| WO2017192997A1 (en) | 2016-05-05 | 2017-11-09 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| GB201614455D0 (en) | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
| NZ753051A (en) * | 2016-11-04 | 2023-03-31 | Children’S Hospital Medical Center | Liver organoid compositions and methods of making and using same |
| US10493363B2 (en) * | 2016-11-09 | 2019-12-03 | Activision Publishing, Inc. | Reality-based video game elements |
| KR102807995B1 (ko) | 2016-12-05 | 2025-05-16 | 칠드런즈 호스피탈 메디칼 센터 | 결장 유사장기 및 이를 제조 및 사용하는 방법 |
| JP7248586B2 (ja) | 2017-04-14 | 2023-03-29 | チルドレンズ ホスピタル メディカル センター | 複数ドナー幹細胞組成物およびそれを作製する方法 |
| WO2018204775A1 (en) | 2017-05-05 | 2018-11-08 | Hepanova, Inc. | Amino-aryl-benzamide compounds and methods of use thereof |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| EP3681537A1 (en) | 2017-09-13 | 2020-07-22 | Novartis AG | Combinations comprising fxr agonists |
| EP3694603A4 (en) | 2017-10-10 | 2021-07-14 | Children's Hospital Medical Center | ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF |
| EP3701953A4 (en) * | 2017-10-27 | 2021-06-16 | Samyang Corporation | COMPOSITION FOR THE PREVENTION OR RELIEF OF NON-ALCOHOLIC FAT LIVER DISEASE |
| IL275002B2 (en) | 2017-12-06 | 2024-04-01 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| SG11202100533VA (en) | 2018-07-26 | 2021-02-25 | Childrens Hospital Med Ct | Hepato-biliary-pancreatic tissues and methods of making same |
| SG11202102431YA (en) | 2018-09-12 | 2021-04-29 | Childrens Hospital Med Ct | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| DK4056176T3 (da) | 2018-09-24 | 2024-05-06 | Amarin Pharmaceuticals Ie Ltd | Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ |
| MX2021005724A (es) * | 2018-11-16 | 2021-07-21 | Cymabay Therapeutics Inc | Tratamiento combinado contra nafld y nash. |
| EP3880187A1 (en) | 2018-11-16 | 2021-09-22 | CymaBay Therapeutics, Inc. | Treatment of obesity and its complications |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CA3141807A1 (en) | 2019-05-31 | 2020-12-03 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021097120A1 (en) | 2019-11-12 | 2021-05-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| US20210145775A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of intestinal barrier dysfunction and associated diseases |
| US20210145774A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of alcoholic liver disease |
| EP4149452A4 (en) * | 2020-05-13 | 2024-05-01 | Terns Pharmaceuticals, Inc. | COMBINATION TREATMENT OF LIVER DISEASES |
| KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
| CA3214214A1 (en) * | 2021-05-11 | 2022-11-17 | Genfit | Ppar-agonists for use in the treatment of liver failure |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US6222025B1 (en) | 1995-03-06 | 2001-04-24 | Isis Pharmaceuticals, Inc. | Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| CA2246229C (en) | 1996-02-14 | 2011-08-23 | Isis Pharmaceuticals Inc. | Sugar-modified gapped oligonucleotides |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7301050B2 (en) | 2003-09-19 | 2007-11-27 | Janssen Pharmaceutical N.V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| KR20060129082A (ko) | 2004-03-05 | 2006-12-14 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과연관된 질환 또는 질병의 치료 방법 |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| WO2008091863A1 (en) | 2007-01-23 | 2008-07-31 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| ES2712052T3 (es) | 2008-10-17 | 2019-05-09 | Cymabay Therapeutics Inc | Métodos para reducir partículas de LDL pequeñas y densas |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AU2014353246A1 (en) | 2013-11-20 | 2016-06-16 | Cymabay Therapeutics, Inc. | Treatment of homozygous familial hypercholesterolemia |
| CN106102734B (zh) | 2014-03-20 | 2019-05-14 | 西玛贝医药公司 | 肝内胆汁淤积性疾病的治疗 |
| PL3129018T3 (pl) | 2014-04-11 | 2020-05-18 | Cymabay Therapeutics, Inc. | Leczenie NAFLD i NASH |
| HK1231380A1 (zh) | 2014-06-26 | 2017-12-22 | Cymabay Therapeutics, Inc. | 严重高甘油三酯血症的治疗 |
-
2015
- 2015-04-10 PL PL15728222T patent/PL3129018T3/pl unknown
- 2015-04-10 BR BR112016023269A patent/BR112016023269A8/pt not_active Application Discontinuation
- 2015-04-10 US US14/684,100 patent/US9381181B2/en active Active
- 2015-04-10 SI SI201531047T patent/SI3129018T1/sl unknown
- 2015-04-10 PH PH1/2016/501978A patent/PH12016501978B1/en unknown
- 2015-04-10 SG SG11201608077PA patent/SG11201608077PA/en unknown
- 2015-04-10 KR KR1020167031356A patent/KR102374499B1/ko active Active
- 2015-04-10 AU AU2015243239A patent/AU2015243239B2/en active Active
- 2015-04-10 NZ NZ72474015A patent/NZ724740A/en unknown
- 2015-04-10 MX MX2016013375A patent/MX369921B/es active IP Right Grant
- 2015-04-10 CA CA2944139A patent/CA2944139C/en active Active
- 2015-04-10 DK DK15728222.9T patent/DK3129018T3/da active
- 2015-04-10 UA UAA201609927A patent/UA121208C2/uk unknown
- 2015-04-10 ES ES15728222T patent/ES2764467T3/es active Active
- 2015-04-10 EA EA201692050A patent/EA036704B1/ru unknown
- 2015-04-10 CN CN201580018550.9A patent/CN106163508A/zh active Pending
- 2015-04-10 EP EP15728222.9A patent/EP3129018B1/en active Active
- 2015-04-10 WO PCT/US2015/025416 patent/WO2015157697A1/en not_active Ceased
- 2015-04-10 RS RS20191583A patent/RS59637B1/sr unknown
- 2015-04-10 JP JP2016561799A patent/JP6865038B2/ja active Active
- 2015-04-10 SM SM20200019T patent/SMT202000019T1/it unknown
- 2015-04-10 HR HRP20192299TT patent/HRP20192299T1/hr unknown
- 2015-04-10 PT PT157282229T patent/PT3129018T/pt unknown
- 2015-04-10 LT LTEP15728222.9T patent/LT3129018T/lt unknown
-
2016
- 2016-06-02 US US15/171,910 patent/US9616039B2/en active Active
- 2016-10-04 CL CL2016002517A patent/CL2016002517A1/es unknown
- 2016-10-05 IL IL248193A patent/IL248193B/en active IP Right Grant
-
2017
- 2017-03-02 US US15/447,895 patent/US9962346B2/en active Active
-
2018
- 2018-04-03 US US15/943,936 patent/US10188620B2/en active Active
- 2018-12-17 US US16/222,379 patent/US10342770B2/en active Active
-
2019
- 2019-05-23 US US16/420,465 patent/US10722483B2/en active Active
- 2019-12-20 CY CY20191101347T patent/CY1122602T1/el unknown
-
2020
- 2020-06-19 US US16/906,296 patent/US11179359B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122602T1 (el) | Αντιμετωπιση των nafld και nash | |
| EP3463464A4 (en) | ASSOCIATION TREATMENT | |
| EP3651772A4 (en) | ANTI-CANCER POLYTHERAPY | |
| ECSP17015977A (es) | Terapia de combinacion | |
| DK3469425T3 (da) | Strålingskilde | |
| DK3212670T3 (da) | Kombinationsterapi mod cancer | |
| SI3283527T1 (sl) | Kombinirana terapija proti raku | |
| EP3601536A4 (en) | TREATMENT PROCESSES | |
| DK3612624T3 (da) | Genterapi | |
| EP3360010A4 (en) | BI PHOTONS WITH VOTABLE SOURCE | |
| DK3468496T3 (da) | Elektrokirurgisk indretning med integreret mikrobølgekilde | |
| IL268463A (en) | Cancer treatment | |
| PL3525774T3 (pl) | Leczenie lazofoksyfenem raka piersi er+ | |
| CY1123019T1 (el) | Σπειροκυκλικες ενωσεις | |
| EP3413927A4 (en) | CANCER THERAPY | |
| EP3807320A4 (en) | POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| EP3512553A4 (en) | KLRG1 EXHAUST THERAPY | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATION CANCER TREATMENT | |
| DK3188599T3 (da) | Medicinske behandlinger baseret på anamorelin | |
| HUE040167T2 (hu) | Rákkezelés | |
| DK3688530T3 (da) | Strålingskilde | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3597225A4 (en) | TREATMENT PROCESS | |
| DK3302478T3 (da) | Pac-1 kombinations behandling |